高级检索
    黄龙, 刘安文, 梅世琪. 奥希替尼联合化疗在伴有EGFR突变晚期非小细胞肺癌一线治疗中的应用[J]. 循证医学, 2024, 24(1): 26-31. DOI: 10.12019/j.issn.1671-5144.2024.01.005
    引用本文: 黄龙, 刘安文, 梅世琪. 奥希替尼联合化疗在伴有EGFR突变晚期非小细胞肺癌一线治疗中的应用[J]. 循证医学, 2024, 24(1): 26-31. DOI: 10.12019/j.issn.1671-5144.2024.01.005
    shu
    HUANG Long, LIU An-wen, MEI Shi-qi. Osimertinib Plus Chemotherapy in the First-Line Treatment of EGFR-Mutant Advanced Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2024, 24(1): 26-31. DOI: 10.12019/j.issn.1671-5144.2024.01.005
    Citation: HUANG Long, LIU An-wen, MEI Shi-qi. Osimertinib Plus Chemotherapy in the First-Line Treatment of EGFR-Mutant Advanced Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2024, 24(1): 26-31. DOI: 10.12019/j.issn.1671-5144.2024.01.005
    shu

    奥希替尼联合化疗在伴有EGFR突变晚期非小细胞肺癌一线治疗中的应用

    Osimertinib Plus Chemotherapy in the First-Line Treatment of EGFR-Mutant Advanced Non-Small Cell Lung Cancer

      摘要
      • HTML全文
      • 参考文献(27)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回